1,520 Alzheimers Headlines
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute
St. Joseph's Hospital and Medical Center
"2 NEW THERAPIES FOR ALZHEIMER'S"
Produced by MD Health Channel
Executive Editor.....Anne-Merete Robbs
CEO..............Stan Swartz

Dr. Reyes and his team are constantly working on new medicines and new solutions...You will receive news alerts...information on new trials as Dr Reyes announces them!
"2 NEW THERAPIES FOR ALZHEIMER'S"
Patricio Reyes M.D., F.A.N.N.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

St. Joseph's Hospital and Medical Center



DO YOU HAVE ALZHEIMERS?
 
"HELP DR. REYES... IN HIS BATTLE TO FIND A CURE...
.HE NEEDS YOUR HELP:
YOU CAN HELP WIN THE BATTLE FOR A CURE BY JOINING A TRIAL!!"....

Stan Swartz, CEO,
The MD Health Channel



"You'll receive all medication and study based procedures at
no charge

if you qualify for one of the many trials being conducted at Barrow Neurological Institute."
 

"Dr. Reyes Changed My Life"

- John Swartz
92 Years Old
Attorney at Law
"Dr.Reyes Changed My Life "
1:18
"At 92...I had lost my will to live"
5:48
Tips on Aging
2:29
"Dr. Reyes gave me customized health care"
2:09

Patricio Reyes M.D.
Director, Traumatic Brain Injury, Alzheimer's Disease & Cognitive Disorders Clinics; Phoenix, AZ; Chief Medical Officer, Retired NFL Players Association

Barrow Neurological Institute

St. Joseph's Hospital and Medical Center
"PRESERVING BRAIN FUNCTIONS "
Runtime: 50:22
Runtime: 50:22
"2 NEW THERAPIES FOR ALZHEIMER'S"
Runtime: 10:27
Runtime: 10:27
ALZHEIMER'S AWARENESS PROGRAMS
Runtime: 5:00
Runtime: 5:00
BIOMEDICAL RESEARCH IN ALZHEIMER'S DISEASE
PDF Document 850 kb

Download Free

4 TALES OF NEUROSURGERY &
A PIANO CONCERT BY DR. SPETZLER...
Plus 2 books written by Survivors for Survivors!
Robert F. Spetzler M.D.
Director, Barrow Neurological Institute

J.N. Harber Chairman of Neurological Surgery

Professor Section of Neurosurgery
University of Arizona
TALES OF NEUROSURGERY:
A pregnant mother..a baby..faith of a husband.. .plus... Cardiac Standstill: cooling the patient to 15 degrees Centigrade!
Lou Grubb Anurism
The young Heros - kids who are confronted with significant medical problems!
2 Patients...confronted with enormous decisions before their surgery...wrote these books to help others!
A 1 MINUTE PIANO CONCERT BY DR. SPETZLER

Michele M. Grigaitis MS, NP
Alzheimer's Disease and Cognitive Disorders Clinic

Barrow Neurological Clinics
COPING WITH DEMENTIA
 
Free Windows Media Player Click

Links
Barrow Neurological Institute

Archives
October 2006  
November 2006  
December 2006  
January 2007  
February 2007  
March 2007  
May 2007  
June 2007  
November 2007  
December 2007  
April 2008  
July 2008  
August 2008  
September 2008  
October 2008  
November 2008  
December 2008  
January 2009  
February 2009  
March 2009  
April 2009  
May 2009  
February 2010  
March 2013  
May 2013  
November 2013  
January 2014  
February 2014  
March 2014  
April 2014  
May 2014  
June 2014  
July 2014  
June 2016  
July 2016  
August 2016  
September 2016  
October 2016  
November 2016  
December 2016  
January 2017  
February 2017  
March 2017  
April 2017  
May 2017  
June 2017  
July 2017  
August 2017  
September 2017  
October 2017  
November 2017  
December 2017  
January 2018  
February 2018  

This page is powered by Blogger. Isn't yours?

Tuesday, March 21, 2017

 

A Drug That Could Slow Parkinson’s and Alzheimer’s Is Heading to Major Testing
























A drug that has already been approved to treat leukemia is now closer to being approved for use against the debilitating brain diseases, parkinson’s and alzheimer’s. There are more than 5 million people currently living with Alzheimer’s disease in the US and another million living with parkinson’s. This drug has the potential to change the lives of not just these millions of sufferers, but also their countless friends and family who suffer along with them.

Currently, there are no approved drugs to slow or halt the progression of the diseases. These patients typically take medications and treatments to address the specific symptoms of their disease, which have their own deleterious side-effects. However, in a previous study, the drug known as nilotinib, “significantly increased brain dopamine (the chemical lost as a result of neuronal destruction) and reduced toxic proteins linked to disease progression.”

“It was such a small trial, there was no placebo control and it really wasn’t designed to assess efficacy,” says J. Paul Taylor, chair of the cell and molecular biology department at St. Jude Children’s Research Hospital. But, researchers are remaining prudent.  To further test and prove the efficacy of this drug, twin trials will be conducted at Georgetown.

“This is going to help us identify what might have been a placebo effect and what is truly the effect of the medication,” says Fernando Pagan, medical director of the translational neurotherapeutics program at Georgetown.

FUELING OPTIMISM

Years of research studying these neurodegenerative diseases has allowed for new treatments like this to be developed. A better understanding of how these diseases work and how they impact the brains of sufferers is leading to better potential treatments.

Trials will be conducted for a year. According to the press release, “The clinical trial is a phase II, randomized, double-blind, placebo-controlled study designed to evaluate the safety and tolerability of low doses of nilotinib, the efficacy on disease biomarkers, and clinical outcomes in people with mid-stage Parkinson’s disease.” The other trial will evaluate the same for alzheimer’s.

NPR spoke with Jonathan Lessin, a retired anesthesiologist who is living with parkinson’s. He expressed great excitement for the potential of this drug. “I’m very optimistic,” he says. “I’ve seen it cure Parkinson’s in mice. I’ve seen people who can talk again, walk again, which is very encouraging.”

Taylor says, “If the results of this trial don’t turn out to be as exciting as the very tiny trial suggested, I would not get too pessimistic because there are other developments that are in the wings.”

Story Source: The above story is based on materials provided by FUTURISM
Note: Materials may be edited for content and length